# argenx

> Developing antibody-based medicines

Business model and tags: B2B, Publicly traded, Multi-product, Pharma & life sciences, Parent company, International operations, Has in-house R&D

## About argenx

Global immunology company focused on developing novel antibody-based medicines for severe autoimmune diseases through collaborations with leading researchers

## Key facts

- **Industry**: Biotechnology Research
- **Company size**: 1,001–5,000 employees
- **Headquarters**: boston, massachusetts, United States
- **Founded**: 2008
- **Revenue**: $4.2B (FY2025, publicly reported)
- **Website**: [argenx.com](https://argenx.com/)
- **LinkedIn**: [linkedin.com/company/argenx](https://www.linkedin.com/company/argenx)

## argenx account plan

argenx is a Dutch-Belgian immunology biotech selling VYVGART, the first approved FcRn blocker: $4.2 billion FY2025 product net sales, 1,863 employees.

[Read the argenx account plan](https://www.tamtam.ai/c/argenx/account-plan)

## argenx at a glance

argenx is a B2B company in the Biotechnology Research industry, headquartered in boston, massachusetts, United States.

argenx was founded in 2008.

argenx has 1,001–5,000 employees.

argenx's revenue is $4.2B (FY2025, publicly reported).

## Frequently asked questions about argenx

### What is argenx's revenue?

argenx's revenue is $4.2B (FY2025, publicly reported).

### How many employees does argenx have?

argenx has 1,001–5,000 employees.

### Where is argenx headquartered?

argenx is headquartered in boston, massachusetts, United States.

---

Company data compiled by Tamtam from public sources and Tamtam's own analysis. Figures marked as estimates are modelled, not reported.

Source: https://www.tamtam.ai/c/argenx
